Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | General Counsel | September 21, 2026 | September 21, 2026 |
| TerraVia Holdings, Inc.TVIA · Entity 175855 | General Counsel | March 09, 2017 | March 13, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date September 21, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,995 |
Ending reported balance
After 2026-09-21 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-21 · Exercise / conversion · Acquired 10,000 · Balance 39,995 Row 2 · 2026-09-21 · Sale · Disposed 2,900 · Balance 37,095 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Row 3 · 2026-09-21 · Sale · Disposed 3,832 · Balance 33,263 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. Row 4 · 2026-09-21 · Sale · Disposed 601 · Balance 32,662 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive. Row 5 · 2026-09-21 · Sale · Disposed 2,667 · Balance 29,995 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive. |
| Employee Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2034-07-14 | Direct | 79,996 |
Reported balance
After 2026-09-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-21 · Exercise / conversion · Disposed 10,000 · Balance 79,996 F6: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive.
F6: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
TerraVia Holdings, Inc.
Report date March 09, 2017 · Filed March 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 218,403 |
Reported balance
After 2017-03-09 transaction · row 1
1 source rowRow 1 · 2017-03-09 · Sale · Disposed 25,000 · Balance 218,403 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan in connection with the concurrent vesting of restrictred stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7601 to $0.9045, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan in connection with the concurrent vesting of restrictred stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7601 to $0.9045, inclusive. The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CymaBay Therapeutics, Inc.
Report date March 22, 2024 · Filed March 22, 2024
Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-22 · Disposition to issuer · Disposed 41,824 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-22 · Disposition to issuer · Disposed 28,438 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2030-10-11 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-22 · Disposition to issuer · Disposed 233,176 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-22 · Disposition to issuer · Disposed 22,167 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-22 · Disposition to issuer · Disposed 107,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-22 · Disposition to issuer · Disposed 215,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-22 · Disposition to issuer · Disposed 105,625 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2026 Filed Sep 21, 2026 20:57 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000100 · form4.xml · derivative · entry 6 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,996 Underlying: Common Stock · 10,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025. Read SEC document |
| September 21, 2026 Filed Sep 21, 2026 20:57 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,667 | $95.31 | $254,195.77 |
DisclosureSEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 5 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,995 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive. Read SEC document |
| September 21, 2026 Filed Sep 21, 2026 20:57 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 601 | $94.44 | $56,760.00 |
DisclosureSEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 4 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,662 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive. Read SEC document |
| September 21, 2026 Filed Sep 21, 2026 20:57 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,832 | $93.32 | $357,591.89 |
DisclosureSEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,263 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. Read SEC document |
| September 21, 2026 Filed Sep 21, 2026 20:57 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,900 | $92.37 | $267,869.81 |
DisclosureSEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,095 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| September 21, 2026 Filed Sep 21, 2026 20:57 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 10,000 | $7.80 | $78,000.00 |
DisclosureSEC source: 0000907654-26-000100 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:14 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,039 | $95.71 | $99,442.69 |
DisclosureSEC source: 0000907654-26-000095 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,995 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · derivative · entry 10 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,500 Underlying: Common Stock · 42,000 shares Expires 2035-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · derivative · entry 9 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,996 Underlying: Common Stock · 10,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,847 | $111.14 | $427,547.12 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 8 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,034 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 9,193 | $110.00 | $1,011,265.85 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 7 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,881 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 10,200 | $109.11 | $1,112,953.62 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 6 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,074 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 14,696 | $107.97 | $1,586,778.56 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 5 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,274 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 10,434 | $107.14 | $1,117,900.85 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 4 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,970 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,630 | $106.05 | $384,962.95 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,404 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 42,000 | $12.50 | $525,000.00 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 10,000 | $7.80 | $78,000.00 |
DisclosureSEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:50 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 733 | $69.69 | $51,082.77 |
DisclosureSEC source: 0000907654-26-000060 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,034 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:04 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 733 | $41.30 | $30,272.90 |
DisclosureSEC source: 0000907654-26-000029 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,767 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000014 · form4.xml · derivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-01-22 F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000014 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:42 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 162,500 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001062993-25-001087 · form4.xml · derivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2035-01-21 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 105,625 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0000950170-24-035453 · ownership.xml · derivative · entry 7 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,625 shares Expires 2034-01-23 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 215,000 | Not disclosed Strike: $7.80 | Not disclosed |
DisclosureSEC source: 0000950170-24-035453 · ownership.xml · derivative · entry 6 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 215,000 shares Expires 2033-01-24 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 107,000 | Not disclosed Strike: $2.94 | Not disclosed |
DisclosureSEC source: 0000950170-24-035453 · ownership.xml · derivative · entry 5 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,000 shares Expires 2032-01-24 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 22,167 | Not disclosed Strike: $5.78 | Not disclosed |
DisclosureSEC source: 0000950170-24-035453 · ownership.xml · derivative · entry 4 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,167 shares Expires 2031-01-25 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 233,176 | Not disclosed Strike: $7.89 | Not disclosed |
DisclosureSEC source: 0000950170-24-035453 · ownership.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 233,176 shares Expires 2030-10-11 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerCommon Stock | 28,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035453 · ownership.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:59 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerCommon Stock | 41,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035453 · ownership.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:02 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 41,824 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001062993-24-006510 · form4.xml · derivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,872 Underlying: Common Stock · 41,824 shares Expires 2030-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option grant vests as to 1/4 of the underlying shares on October 12, 2021 and as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:02 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 41,824 | $7.89 | $329,991.36 |
DisclosureSEC source: 0001062993-24-006510 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 18:28 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 105,625 | $0.00 Strike: $22.85 | $0.00 |
DisclosureSEC source: 0001062993-24-001429 · form4.xml · derivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,625 Underlying: Common Stock · 105,625 shares Expires 2034-01-23 F2 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2024. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 18:28 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantCommon Stock | 28,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001429 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,438 F1 · shares: The grant shall vest as to 1/4 of the shares on each of January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028. Read SEC document |
| January 16, 2024 Filed Jan 16, 2024 19:07 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-24-000923 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| January 16, 2024 Filed Jan 16, 2024 19:07 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $23.58 | $117,898.00 |
DisclosureSEC source: 0001062993-24-000923 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $23.70, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2024 Filed Jan 16, 2024 19:07 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-24-000923 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2023 Filed Dec 15, 2023 16:35 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-022636 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| December 15, 2023 Filed Dec 15, 2023 16:35 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $21.98 | $109,902.50 |
DisclosureSEC source: 0001062993-23-022636 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Dec 15, 2023 16:35 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-022636 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-021137 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $17.38 | $86,889.00 |
DisclosureSEC source: 0001062993-23-021137 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.55, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-021137 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 18:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-019547 · form4.xml · derivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 18:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 5,000 | $13.76 | $68,798.00 |
DisclosureSEC source: 0001062993-23-019547 · form4.xml · nonDerivative · entry 2 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.65 to $13.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 18:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001062993-23-019547 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 53,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-23-018278 · form4.xml · derivative · entry 7 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,000 Underlying: Common Stock · 53,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 24,000 | $16.87 | $404,916.00 |
DisclosureSEC source: 0001062993-23-018278 · form4.xml · nonDerivative · entry 6 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 24,000 | $2.94 | $70,560.00 |
DisclosureSEC source: 0001062993-23-018278 · form4.xml · nonDerivative · entry 5 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 24,000 | $16.87 | $404,896.80 |
DisclosureSEC source: 0001062993-23-018278 · form4.xml · nonDerivative · entry 4 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 24,000 | $2.94 | $70,560.00 |
DisclosureSEC source: 0001062993-23-018278 · form4.xml · nonDerivative · entry 3 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.